Post-Marketing Surveillance of REGKIRONA ® 960mg (Regdanvimab)(monoclonal antibody, gene recombination) to Evaluate Its Safety and Efficacy (CT-P59 4.1)

First published 12/04/2022

Last updated 23/04/2024

EU PAS number:

EUPAS46141

Study

Ongoing

Download as PDF

Documents

Study protocol

No information provided.

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Post-Marketing Surveillance of REGKIRONA ® 960mg (Regdanvimab)(monoclonal antibody, gene recombination) to Evaluate Its Safety and Efficacy (CT-P59 4.1)

Secondary tabs

Share this page